A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To evaluate the safety and tolerability of SAR245409 tablets administered once or twice a
day in patients with solid tumors or lymphoma.
Secondary Objectives:
- To evaluate blood levels of SAR245409 after administration of SAR245409 tablets once or
twice a day in patients with solid tumors or lymphoma.
- To evaluate the effect of food on blood levels of SAR245409 after administration of
SAR245409 tablets in patients with solid tumors or lymphoma.
- To evaluate the effect of SAR245409 on the body after administration of SAR245409
tablets once or twice a day in patients with solid tumors or lymphoma.
- To obtain information on how SAR245409 administered once or twice a day to patients with
solid tumors or lymphoma affect disease symptoms and study treatment side effects as
reported by the patients on a questionnaire.
- To explore the antitumor activity of SAR245409 tablets administered once or twice a day
to patients with solid tumors or lymphoma.